Associate Professor, Pediatrics and Leukemia
Pediatric Hematology & Oncology
Dr. Michael E. Rytting, MD
|
|
Give Review
Michael E. Rytting, MD works in the field of Pediatric Hematology & Oncology. He researched medicine at University of Michigan Medical School. He received 1 awards: "Regional Top Doctor". Michael E. Rytting is also a published doctor. He has 42 publication published. The most recent publication is: Acute reversible arthropathy in a pediatric patient with cancer treated with a short course of ciprofloxacin for febrile neutropenia. He accepts all Medicare patients.
Publications
- Prognostic factors for outcome in patients with refractory and relapsed Acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody.
- A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed / Refractory Acute Lymphoblastic Leukemia.
- Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory Acute lymphocytic leukaemia.
- Asparaginase in Acute Lymphoblastic Leukemia.
- Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with Acute lymphoblastic leukemia (ALL).
- Acting on minimal residual Disease in ALL.
- Pediatric patients with refractory central Nervous system tumors: experiences of a clinical trial combining bevacizumab and temsirolimus.
- Impact of aberrant DNA methylation patterns including CYP1B1 methylation in adolescents and young adults with Acute lymphocytic leukemia.
- Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell Acute lymphoblastic leukemia.
- Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed Acute lymphocytic leukemia.
- Preliminary experience with personalized and targeted therapy for pediatric Brain tumors.
- Advanced atypical teratoid/rhabdoid tumor (ATRT) treated with intensive multimodal approach shows continued response to Sarcoma type salvage therapy.
- Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experience.
- Epoetin alpha decreases the number of erythrocyte transfusions in patients with Acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: Re...
- Palliative Reirradiation for Progressive Diffuse Intrinsic Pontine Glioma.
- A rapidly growing Lymphoma and tumor lysis syndrome in a toddler.
- Acute lymphoblastic leukemia with Burkitt-like morphologic features and high myeloperoxidase activity.
- Unusual expression of CD94 on CD8+ TCR-alpha beta T Cells in infectious mononucleosis.
- Complete remission following clofarabine treatment in refractory juvenile myelomonocytic Leukemia.
- Pediatric Myelodysplastic syndromes.
- Central nervous system relapse in two patients with chronic myelogenous Leukemia in myeloid blastic phase on imatinib mesylate therapy.
- Phase II trial of 5-fluorouracil, folinic acid and recombinant alpha-2a-interferon in patients with advanced colorectal Cancer.
- Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced Leukemia.
- Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with Acute leukemia.
- Phase II study of clofarabine in pediatric patients with refractory or relapsed Acute myeloid leukemia.
- Phase II study of clofarabine in pediatric patients with refractory or relapsed Acute lymphoblastic leukemia.
- Impact of age on outcome of pediatric Acute myeloid leukemia: a report from 2 institutions.
- Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with Leukemia.
- Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel.
- Peg-asparaginase for Acute lymphoblastic leukemia.
- Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with Cancer.
- Intensively timed combination chemotherapy for the induction of adult patients with Acute myeloid leukemia: long-term follow-up of a phase 2 study.
- Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult Acute lymphoblastic leukemia salvage therapy.
- Induction treatment for diffuse intrinsic pontine glioma, experience of M.D. Anderson Cancer Center.
- A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed Acute leukemia.
- Hemolytic disorders associated with Cancer.
- Acute reversible arthropathy in a pediatric patient with cancer treated with a short course of ciprofloxacin for febrile neutropenia.
- Economic and resource utilization analysis of outpatient management of fever and neutropenia in low-risk pediatric patients with Cancer.
- Outpatient treatment of fever and neutropenia for low risk pediatric Cancer patients.
- Osteosarcoma in preadolescent patients.
- Haemophagocytic lymphohistiocytosis presenting as Liver failure following Epstein-Barr and prior hepatitis A infections.
Schools
Univ Of Mi Med Sch
University Tex Health Science Center
University Tex Health Science Ctrhermann Hospital
MD Anderson Canc Center
Procedures Preformed
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Brain Cancer
- View All
Doctors Specialties
- Pediatric Hematology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
Education
-
University of Texas Health Science Center -
University of Michigan Medical School
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1548366628 | |
| NPPES Provider LastName | RYTTING | |
| NPPES Provider FirstName | MICHAEL | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Pediatric Medicine | |
| Total Claim Count | 73.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1548366628 |
| Last Name Of The Provider | RYTTING |
| First Name Of The Provider | MICHAEL |
| View All |
Similar Doctors
|
|
Dr. Donald Mahoney, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Laurence Cooper, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Alex George, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jessica A. Shafer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Demetrios Petropoulos, MD
This Doctor is OpenDoctor Recommended.
|